MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$2,862K
Proceeds from issuance of
pre-funded warrants, net of...
$2,584K
Proceeds from short-term
convertible debt
$327K
Net cash provided by
financing activities
$5,324K
(21.69%↑ Y/Y)
Canceled cashflow
$203K
Net decrease in cash
and cash...
$2,033K
(139.55%↑ Y/Y)
Canceled cashflow
$3,291K
Repayments of short-term
borrowing
$203K
Accounts payable and
accrued expenses
$971K
(250.31%↑ Y/Y)
Stock-based compensation
expense
$707K
(-44.77%↓ Y/Y)
Prepaid expenses
-$492K
(-144.40%↓ Y/Y)
Other current assets
-$403K
(-2138.89%↓ Y/Y)
Amortization of operating
lease right-of-use...
$95K
(-62.60%↓ Y/Y)
Depreciation expense
$66K
(-41.59%↓ Y/Y)
Net cash used in
operating activities
-$3,291K
(64.46%↑ Y/Y)
Canceled cashflow
$2,734K
Net loss
-$4,117K
Research and development
supplies and other...
$1,807K
Operating lease liability
-$69K
(72.40%↑ Y/Y)
Gain on termination
of operating lease
$32K
Back
Back
Cash Flow
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)
source: myfinsight.com